First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma. - MPM-MESODEC

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2015
This article has no abstract
Epistemonikos ID: a9a8028d9564162ed18c76b1cec850e717c3d459
First added on: Apr 17, 2025